UCB SA – OTC:UCBJY

UCB SA stock price today

$112.2
+11.79
+11.75%
Financial Health
0
1
2
3
4
5
6
7
8
9

UCB SA stock price monthly change

+27.93%
month

UCB SA stock price quarterly change

+27.93%
quarter

UCB SA stock price yearly change

+129.28%
year

UCB SA key metrics

Market Cap
15.93B
Enterprise value
39.15B
P/E
73.82
EV/Sales
5.77
EV/EBITDA
26.69
Price/Sales
5.38
Price/Book
2.11
PEG ratio
1.20
EPS
2.69
Revenue
7.84B
EBITDA
1.98B
Income
514.5M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
3.77%
Oper. margin
8.59%
Gross margin
65.92%
EBIT margin
8.59%
EBITDA margin
25.25%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

UCB SA stock price history

UCB SA stock forecast

UCB SA financial statements

UCB SA (OTC:UCBJY): Profit margin
Mar 2023 1.25B 155.5M 12.35%
Jun 2023 2.58B 311M 12.01%
Sep 2023 1.33B 16M 1.2%
Dec 2023 2.66B 32M 1.2%
UCB SA (OTC:UCBJY): Analyst Estimates
2025 6.92B 660.51M 9.54%
2026 7.71B 855.15M 11.08%
2027 8.48B 1.04B 12.35%
2028 9.10B 1.22B 13.42%
  • Analysts Price target

  • Financials & Ratios estimates

0.47%
Yield TTM
UCB SA (OTC:UCBJY): Payout ratio
Payout ratio 101.17%
UCB SA (OTC:UCBJY): Dividend Yield
2019 3.38%
2020 2.83%
2021 2.54%
2022 3.55%
2023 3.3%
UCB SA (OTC:UCBJY): Debt to assets
Mar 2023 15382000000 6.34B 41.22%
Jun 2023 15382000000 6.33B 41.21%
Sep 2023 15539000000 6.56B 42.24%
Dec 2023 15539000000 6.56B 42.24%
UCB SA (OTC:UCBJY): Cash Flow
Mar 2023 124.5M -136.5M -183.5M
Jun 2023 148M -273M -266M
Sep 2023 256M -83.5M 29.5M
Dec 2023 469M -167M 102M

UCB SA alternative data

UCB SA (OTC:UCBJY): Employee count
Aug 2023 8,108
Sep 2023 8,600
Oct 2023 8,600
Nov 2023 8,600
Dec 2023 8,600
Jan 2024 8,600
Feb 2024 8,600
Mar 2024 8,450
Apr 2024 8,450
May 2024 8,450
Jun 2024 8,450
Jul 2024 8,450

UCB SA other data

  • What's the price of UCB SA stock today?

    One share of UCB SA stock can currently be purchased for approximately $112.2.

  • When is UCB SA's next earnings date?

    Unfortunately, UCB SA's (UCBJY) next earnings date is currently unknown.

  • Does UCB SA pay dividends?

    Yes, UCB SA pays dividends and its trailing 12-month yield is 0.48% with 101% payout ratio.It means that the company is paying a dividend greater than earnings. The last UCB SA stock dividend of undefined was paid on 4 Sep 2025.

  • How much money does UCB SA make?

    UCB SA has a market capitalization of 15.93B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 4.8% to 5.25B US dollars.

  • What is UCB SA's stock symbol?

    UCB SA is traded on the OTC under the ticker symbol "UCBJY".

  • What is UCB SA's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of UCB SA?

    Shares of UCB SA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does UCB SA have?

    As Jul 2024, UCB SA employs 8,450 workers.

  • When UCB SA went public?

    UCB SA is publicly traded company for more then 6 years since IPO on 30 Nov 2018.

  • What is UCB SA's official website?

    The official website for UCB SA is ucb.com.

  • How can i contact UCB SA?

    UCB SA can be reached via phone at +32 2 559 99 99.

UCB SA company profile:

UCB SA

ucb.com
Exchange:

OTC

Full time employees:

8,600

Industry:

Biotechnology

Sector:

Healthcare

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, Italy, the United Kingdom, Ireland, China, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

AllEe de la Recherche, 60
Brussels, 1070

:
ISIN: US9034801012
CUSIP: 903480101